Melbourne, Apr 9, 2008 (ABN Newswire) - Australia’'s adult stem cell company, Mesoblast Limited (ASX: MSB)(USOTC: MBLTY), today announced that it will accelerate its clinical trial timetable towards commencement of a Phase 3 trial in spinal fusion by mid 2009 following encouraging preliminary safety data from its ongoing Phase 2 clinical trial.
